STOCK TITAN
  1. Home
  2. News
  3. LNTH

Lantheus Holdings Inc - LNTH STOCK NEWS

Welcome to our dedicated news page for Lantheus Holdings (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lantheus Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lantheus Holdings's position in the market.

News
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
Rhea-AI Summary
Lantheus Holdings, Inc. (LNTH) has entered into strategic agreements with Perspective Therapeutics, Inc. (CATX), a radiopharmaceutical company, including an option to license Perspective’s Pb212-VMT-⍺-NET asset, co-development rights for certain Pb212-based alpha therapies for prostate cancer, and an equity investment of up to 19.9% in Perspective Therapeutics. Perspective Therapeutics also intends to acquire a radiopharmaceutical manufacturing facility in Somerset, NJ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
none
-
News
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
Rhea-AI Summary
Lantheus Holdings, the leading radiopharmaceutical-focused company (NASDAQ: LNTH), expects a 38-39% increase in full year 2023 worldwide revenue, with PYLARIFY revenue projected to increase by 61-62% and DEFINITY revenue by 14%. Preliminary unaudited financial results show a significant impact on patient lives and record revenues, positioning the company for sustained shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
earnings
-
News
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Lantheus Holdings, Inc. (LNTH) announced CEO Mary Anne Heino will present at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation will be available via live webcast and replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
conferences
News
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Rhea-AI Summary
Lantheus Holdings, Inc. (LNTH) and POINT Biopharma Global Inc. (PNT) announce statistically significant topline results from the Phase 3 SPLASH study of 177Lu-PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor (ARPI). The study demonstrated a median radiographic progression-free survival (rPFS) of 9.5 months for patients treated with 177Lu-PNT2002, compared to 6.0 months for patients treated with ARPI, representing a statistically significant 29% reduction in the risk of radiographic progression or death. The trial also showed a favorable safety profile for 177Lu-PNT2002.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.88%
Tags
clinical trial
-
News
Lantheus to Present at the Jefferies London Healthcare Conference
Rhea-AI Summary
Lantheus Holdings, Inc. (NASDAQ: LNTH) announces participation in Jefferies London Healthcare Conference. Paul Blanchfield, President, and Bob Marshall, CFO, to present at 8:00 a.m. GMT on November 15. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
conferences
-
News
Lantheus Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Lantheus Holdings, Inc. reported a worldwide revenue of $319.9 million for Q3 2023, a 33.7% increase from the prior year period. GAAP net income was $132.0 million, compared to $61.2 million in the prior year period. Adjusted fully diluted net income per share was $1.47, up from $0.99 in the prior year period. Net cash provided by operating activities was $116.7 million. The company updates its full year 2023 revenue and adjusted diluted earnings per share guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.95%
Tags
earnings
News
Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a.m. Eastern Time
Rhea-AI Summary
Lantheus Holdings to host conference call and webcast to discuss Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
conferences earnings
-
News
Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting
Rhea-AI Summary
Lantheus Holdings to present PYLARIFY AI data at EANM Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
AI
-
News
Lantheus to Present at the Wells Fargo Healthcare Conference
Rhea-AI Summary
Lantheus Holdings to present at Wells Fargo Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
conferences
News
Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty
Rhea-AI Summary
Lantheus Holdings, Inc. (NASDAQ: LNTH) announces divestiture of RELISTOR net sales royalties, enhancing focus on core radiopharmaceutical business. HealthCare Royalty acquires royalty rights, providing Lantheus with initial payment of $98 million and potential additional payment of $5 million if 2025 net sales exceed a specified threshold.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.71%
Tags
none
Stock LNTH logo
Lantheus Holdings Inc

Nasdaq:LNTH

LNTH Rankings

#1280 Ranked by Market Cap
#2662 Ranked by Stock Gains
N/A Ranked by Dividends

LNTH Stock Data

4.17B
67.08M
2.57%
104.79%
6.89%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
North Billerica

About LNTH

lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.